BioSpace News Archive

BD, a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel, a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus, has been CE marked to the IVD directive 98/79/EC.

Immunovia announced the PanDIA-1 study for the early detection of pancreatic cancer in newly onset type 2 diabetics is moving into the next phase.

BeiGene announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma without prior systemic treatment for advanced disease.

During June, Calliditas Therapeutics AB has issued 5,908,018 class C-shares as part of the establishment of the company’s at-the-market program.

Ermium Therapeutics announced the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partners.

Avacta Group plc is pleased to announce that LG Chem Life Sciences, the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million.

Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes research data on its novel immune-evasive universal CAR T-cells in Nature Communications.

Uro Medical Corporation announced the Center for Medicare and Medicaid Services coverage for participants in the GUARDIAN™ clinical trial, a multi-center randomized controlled clinical study evaluating the safety and efficacy of the Protect PNS neurostimulator medical device, as compared to traditional pharmaceutical medical management for the treatment for overactive bladder.

Galderma is entering its tenth year of partnership with Camp Wonder. Founded by the Children’s Skin Disease Foundation, Camp Wonder is a medically-staffed summer camp program for children ages 7 to 16 with serious skin diseases.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets.